OnCo
companiesCompany

Champions Oncology

Oncology CRO with the largest bank of patient-derived xenograft models (TumorGraft), now adding 3D organoid screening and radiopharmaceutical services.

More than 1,400 clinically annotated PDX models with correlation to patient outcomes; TumorGraft3D organoid platform; AstraZeneca collaboration; fiscal 2026 revenue $59.4M (record) with positive adjusted EBITDA.

Headquarters
Hackensack, NJ, US
Type
cro services · CSBR

Connected

8top

fronts

1
Drug Discovery Platforms

technologies

2
Patient-derived organoidsPatient-derived xenografts

ideas

4
Humanised mice with an immune system matched to the tumour donorMulti-laboratory preclinical trials as the standard for go/no-go decisionsRun the mouse or organoid trial at the same time as the human trialTest drugs on the patient's own cancer cells when there is no trial to join

bottlenecks

1
Preclinical models that do not predict people